Rational Vaccines

Executive Summary

Rational Vaccines is a private, investigational-stage biotechnology company pioneering next-generation vaccines for herpes simplex virus (HSV-1 and HSV-2). The company's platform leverages rationally engineered, live-attenuated viral strains designed to elicit robust immune responses while minimizing pathogenicity. Their lead candidates include both therapeutic and prophylactic vaccines, aiming to reduce viral shedding, prevent transmission, and potentially achieve sterilizing immunity. Founded in 2015 and headquartered in Boston, the company operates with a mission to revolutionize herpes management worldwide, addressing a significant unmet medical need given the lack of approved vaccines for these ubiquitous viruses. With a rational design approach that distinguishes it from prior attempts, Rational Vaccines has attracted attention from researchers and investors focused on infectious disease innovation. Currently, the company is advancing its candidates through preclinical and early clinical development. While specific pipeline details are limited, the potential for a first-in-class HSV vaccine represents a multibillion-dollar market opportunity. Key risks include the historical difficulty of HSV vaccine development, regulatory challenges, and the need for substantial funding to progress through clinical trials. Success could transform the lives of the estimated 3.7 billion people globally infected with HSV-1 and 491 million with HSV-2, reducing stigma and disease burden. The company's progress will be closely watched by the vaccine community, and upcoming milestones will be critical in validating its approach.

Upcoming Catalysts (preview)

• TBDInitiation of Phase 1 Clinical Trial for Prophylactic Vaccine Candidate40% success
• TBDIND Filing for Therapeutic Vaccine Candidate50% success
• TBDStrategic Partnership or Licensing Deal35% success